-
These Pharma Companies Join Forces To Bring Medical Cannabis Products To Czech & Swiss Markets
Thursday, October 6, 2022 - 7:46am | 476Panaxia (TASE: PNAX), a cannabis-focused pharmaceutical company and European specialty pharmaceutical company Neuraxpharm Group announced on Thursday the signing of two addendums to their agreement to expand their collaboration into the Czech and Swiss markets. What Happened? The collaboration...
-
Panaxia Confirms First Export Of Medical Cannabis Sublingual Tablets To France
Monday, January 24, 2022 - 9:43am | 532Cannabis-focused pharma company Panaxia Labs Israel (TASE:PNAX) (OTCEM:PXLIF) and a subsidiary of Panaxia Global, together with Neuraxpharm Group announced Monday a first export of medical cannabis sublingual tablets from Israel to France. Neuraxpharm is a European specialty pharmaceutical company...
-
Panaxia's Malta Facility Granted EU-GMP Standard, Enabling Export Of Its Products Across Various EU Countries
Monday, January 3, 2022 - 9:31am | 357Panaxia Global (TASE: PNAX), which owns medical cannabis company Panaxia Labs Israel Ltd., has obtained official authorization from the EU Health Authority for the EU-GMP standard for its production facility in Malta. This standard, which is binding and essential for the production...
-
Panaxia & Neuraxpharm Launch Medical Cannabis Extracts In Europe, More Products To Come
Wednesday, December 8, 2021 - 11:36am | 417Medical cannabis producer Panaxia Labs Israel Ltd. (TASE: PNAX), a subsidiary of Panaxia Global (TASE: PNAX) and Neuraxpharm, a European company that specializes in the central nervous system have launched sales of medical cannabis extracts under the joint Brand: Naxiva-Panaxol...
-
Panaxia Labs Israel Reports Q3 Record Revenues Of $7.15M, Up 34% YoY
Tuesday, November 30, 2021 - 11:28am | 373Medical cannabis company Panaxia Labs Israel Ltd., a subsidiary of Panaxia Global (TASE: PNAX), reported its financial results on Monday for the third quarter revealing revenues of NIS22.5 million ($7.15 million), up by 34% from NIS16.8 million in the same period of last year. The...
-
Panaxia Q2 Revenue Grows 19.2% Reaching $5.49M, Sells Its Secondary Operations In Israel
Thursday, September 2, 2021 - 11:40am | 533Panaxia Labs Israel Ltd. (TASE: PNAX) (OTCPK: PXLIF) a subsidiary of Panaxia Global released its financial reports on Thursday for the second quarter and first half of 2021, revealing second-quarter revenues of NIS17.6 million ($5.49 million), up by 19.2% from NIS14.8 million in the same quarter of...
-
Panaxia and Neuraxpharm To Exclusively Distribute Medical Cannabis Extracts For Inhalation In European Market
Monday, June 21, 2021 - 11:08am | 372Israel's largest manufacturer and home-delivery distributor of medical cannabis products, Panaxia Labs Israel Ltd., and its German partner Neuraxpharm received the green light to market and distribute medical cannabis extracts for inhalation, making them the first to...